Phase 2 multicenter randomized semi-single blind study to compare efficacy and safety of high-dose short duration daptomycin with conventional therapy in complicated skin and skin structure infections due to Gram-positive bacteria

Trial Profile

Phase 2 multicenter randomized semi-single blind study to compare efficacy and safety of high-dose short duration daptomycin with conventional therapy in complicated skin and skin structure infections due to Gram-positive bacteria

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Daptomycin (Primary) ; Penicillins; Vancomycin; Vancomycin
  • Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 01 Sep 2008 Results published in International Journal of Clinical Practice.
    • 17 Oct 2007 Status changed from recruiting to completed.
    • 20 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top